secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001214659-24-008007
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro annual meeting results: reverse split approved, Proposal 3 vote adjourned
--------------------------------------------------------------------------------

- All eight director nominees elected; Baker Tilly ratified as auditor for FY ending April 30, 2024.
- Reverse stock split approved (ratio 1:2 to 1:20, board to set by April 29, 2025).
- Proposal 3 (issuance of up to 6M shares to Ault Lending LLC) lacked sufficient votes; meeting adjourned to May 13, 2024 for further voting.
- Outstanding shares: 6,849,407 common and 1,220,000 Series B preferred as of March 14, 2024 record date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008007/0001214659-24-008007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465924008007/p4302408k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-24-008007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer